60 Degrees Pharmaceuticals, Inc. (SXTP)

From the record

60 Degrees Pharmaceuticals, Inc.'s filings since 2022 show 4 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-01-23); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2023-11-15) (its current reports).

From the record

60 Degrees Pharmaceuticals, Inc.'s 4 filed years say what it did: revenue went from $223 thousand in fiscal 2022 to $1 million in fiscal 2025, up 65.1% a year; it rose in 3 of 3 years; it never fell from a peak; net income was positive in 0 of 4 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, 60 Degrees Pharmaceuticals, Inc. lost about 218 cents for every dollar of shareholders' money, and gross profitability: its products earned about 4 cents per dollar of everything the company owns. Leverage: it owed about 37 cents per dollar of assets, and net share issuance: its share count grew 489.6% over the year (the filed statements).

From the record

60 Degrees Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 22% by size; a net margin of -732.5% ranks in the bottom 34%; revenue growth of 65.1% a year over the last 3 filed years ranks in the top 19% (its annual reports).

From the record

60 Degrees Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dow, Geoffrey S (President and CEO, as filed), filing under that title since the record of its people begins (2023-07-11), so the years before are not on the record and this part is not read; the 3 officers and directors filing in the last fifteen months have been on the record a median of 1.8 years (bottom 6%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 3 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

60 Degrees Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against debt of $150 thousand leaves 25.3% of its assets as net cash, bottom 47% of its family; cash from operations less capital spending is -695.1% of revenue (bottom 30%); a gross margin of 22.3% (bottom 13%); research spending of 209.5% of revenue (top 42%) (its annual report).

From the record

60 Degrees Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 65.1% a year over the last three filed years against 65.1% over all 4, speeding up (top 40% of its family); the newest year grew 65.5% (top 20%); research spending grew 58.8% a year (top 6%); capital spending grew 55.8% a year (top 13%) (its annual reports). 60 Degrees Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

60 Degrees Pharmaceuticals, Inc.'s newest year against its own record: revenue of $1 million in fiscal 2025 came in 0.3% above the $1 million its prior three years' pace pointed to (top 45% of its family); net income of $7 million against a prior three-year average of $6 million (bottom 32%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 14%) (its annual reports).